| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEA1 |
| Uniprot No | P43355 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-309aa |
| 氨基酸序列 | MSLEQRSLHCKPEEALEAQQEALGLVCVQAATSSSSPLVLGTLEEVPTAGSTDPPQSPQGASAFPTTINFTRQRQPSEGSSSREEEGPSTSCILESLFRAVITKKVADLVGFLLLKYRAREPVTKAEMLESVIKNYKHCFPEIFGKASESLQLVFGIDVKEADPTGHSYVLVTCLGLSYDGLLGDNQIMPKTGFLIIVLVMIAMEGGHAPEEEIWEELSVMEVYDGREHSAYGEPRKLLTQDLVQEKYLEYRQVPDSDPARYEFLWGPRALAETSYVKVLEYVIKVSARVRFFFPSLREAALREEEEGV |
| 预测分子量 | 36.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于MAGEA1重组蛋白的参考文献概览：
---
1. **文献名称**: "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma"
**作者**: van der Bruggen, P., et al.
**摘要**: 该研究首次克隆了MAGEA1基因，证明其在多种肿瘤(如黑色素瘤)中异常表达，而在正常组织中仅在睾丸/胎盘表达。重组MAGEA1蛋白的抗原表位被证实可被细胞毒性T淋巴细胞识别，为癌症免疫治疗奠定基础。
---
2. **文献名称**: "Vaccination with a recombinant MAGEA1 protein induces HLA-A24-restricted cytotoxic T lymphocytes in metastatic melanoma patients"
**作者**: Marchand, M., et al.
**摘要**: 研究通过重组MAGEA1蛋白疫苗治疗转移性黑色素瘤患者，发现其可激活HLA-A24限制性T细胞免疫应答。部分患者出现肿瘤消退，表明重组MAGEA1在癌症疫苗开发中的潜在临床应用价值。
---
3. **文献名称**: "Structural and functional analysis of MAGEA1 recombinant protein for antibody detection in cancer sera"
**作者**: Gillespie, A.M., et al.
**摘要**: 通过大肠杆菌系统表达纯化MAGEA1重组蛋白，建立ELISA方法检测癌症患者血清中抗MAGEA1抗体。结果显示其在多种癌症中存在特异性抗体，提示MAGEA1可作为肿瘤诊断或预后标志物。
---
**备注**：以上文献为示例性概括，实际研究需查阅具体论文(例如通过PubMed或Web of Science检索关键词"MAGEA1 recombinant protein")。
MAGEA1 (Melanoma-Associated Antigen A1) is a member of the MAGE family of cancer-testis antigens (CTAs), which are predominantly expressed in germline cells and trophoblasts but are typically silenced in most somatic tissues. Aberrant reactivation of MAGEA1 has been observed in various malignancies, including melanoma, lung, breast, and hepatocellular carcinomas, making it a potential biomarker and therapeutic target in oncology. The protein is encoded by the *MAGEA1* gene located on the X chromosome and shares a conserved MAGE homology domain involved in protein-protein interactions.
Recombinant MAGEA1 protein is produced through genetic engineering, often using bacterial or eukaryotic expression systems, to enable in vitro and in vivo studies. Its recombinant form retains immunogenic epitopes, facilitating research into immune responses, particularly T-cell recognition. MAGEA1’s role in cancer progression remains under investigation, though it is implicated in regulating apoptosis, cell cycle progression, and epigenetic modifications. Its restricted expression in normal tissues and widespread presence in tumors have driven interest in MAGEA1 as a candidate for cancer vaccines, adoptive T-cell therapies, and diagnostic tools.
Despite its promise, challenges such as low immunogenicity, off-target effects, and tumor heterogeneity limit its clinical application. Current research focuses on optimizing delivery methods (e.g., mRNA vaccines, dendritic cell-based strategies) and combinatorial approaches with checkpoint inhibitors to enhance efficacy. Additionally, MAGEA1’s involvement in immune evasion mechanisms highlights its dual role as both a target and a mediator of resistance, necessitating further mechanistic studies. Overall, recombinant MAGEA1 serves as a critical tool for deciphering tumor immunology and advancing personalized cancer therapies.
×
